With Three Years of Cash in the Bank, Regulus Aims for Two INDs by 2014
With Three Years of Cash in the Bank, Regulus Aims for Two INDs by 2014
Filed under: drug treatment news 2010
The management of Regulus Therapeutics last week provided a few new details on the company's pipeline, promising that it would have two microRNA drug candidates ready for clinical trials before the end of next year. … ones in liver cancer and kidney …
Read more on RNAi News
Obama's cabinet: Who's in, who's out?
Filed under: drug treatment news 2010
His role has seen a number of challenges as veterans return from both Iraq and Afghanistan with a host of needs, ranging from treatment for physical and mental injuries to job placement as they leave the service to drug addiction and homelessness. It …
Read more on CNN
Bristol-Myers' Eliquis To Exploit The NVAF Market Post Approval In The EU
Filed under: drug treatment news 2010
The NVAF treatment market is currently dominated by generic drug Warfarin and patented drugs, Pradaxa and Xarelto. Pradaxa is owned by Boehringer Ingelheim and received U.S. approval in late 2010. Xarelto is co-promoted by Johnson & Johnson and …
Read more on Trefis
Wonkbook: Thanksgiving's over, but the fiscal talks are just beginning.
Filed under: drug treatment news 2010
According to a new analysis by the Tax Policy Center, Obama could agree to such a deal without adding much more to the deficit than a Senate bill that extends for a year most of the 2001-2010 tax cuts for those making $ 250,000. TPC figures …
Read more on Washington Post (blog)